Morgan Stanley Pardes Biosciences, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.4 - $1.95 $211,169 - $294,128	-150,835 Reduced 86.0%	24,549 $44,000
Q1 2023 May 15, 2023	BUY	$1.21 - $2.22 $187,879 - $344,703	155,272 Added 772.04%	175,384 $231,000
Q4 2022 Feb 14, 2023	SELL	$0.85 - $1.69 $26,852 - $53,388	-31,591 Reduced 61.1%	20,112 $33,000
Q3 2022 Nov 14, 2022	BUY	$2.14 - $3.7 $16,212 - $28,031	7,576 Added 17.17%	51,703 $95,000
Q2 2022 Oct 27, 2022	BUY	$2.84 - $8.57 $117,473 - $354,489	41,364 Added 1497.07%	44,127 $135,000
Q2 2022 Aug 15, 2022	BUY	$2.84 - $8.57 $117,473 - $354,489	41,364 Added 1497.07%	44,127 $135,000
Q1 2022 Oct 27, 2022	SELL	$5.64 - $15.64 $233,292 - $646,932	-41,364 Reduced 93.74%	2,763 $20,000
Q1 2022 May 13, 2022	BUY	$5.64 - $15.64 $15,583 - $43,213	2,763 New	2,763 $20,000

5.23M

Ticker PRDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,320,900
Description
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.